Friday, June 20, 2025 6/20/2025

Comprehensive functional assesment of the human antibody response to Enterovirus 71

Award Number: R21AI119368
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/13/2016
PERIOD OF PERFORMANCE END DATE: 03/31/2019

Group Awards By:

View Award Description

Comprehensive functional assesment of the human antibody response to Enterovirus 71 - ¿ DESCRIPTION (provided by applicant): Enterovirus 71 (EV71) is an emerging picornavirus that has become endemic in Asia-Pacific regions. EV71 infection commonly manifests in childhood as an exanthem known as hand, foot, and mouth disease (HFMD), but in children under the age of 5, severe complications may occur, such as brainstem and/or cerebellar encephalitis, aseptic meningitis, and acute flaccid paralysis. The most devastating complication of EV71 neurologic disease is neurogenic cardiac failure with pulmonary edema. This syndrome can be fatal within hours of onset. There are no specific anti-viral drugs or vaccines approved for EV71 disease. But, in endemic areas, intravenous immunoglobulins (IVIG) are a standard component of supportive care, as IVIG in those regions have significant EV71 IgG titers. Should EV71 spread to non-endemic areas, such as the United States, IVIG will not be useful due to low EV71 IgG titers. Essentially nothing is known about the human antibody response to EV71 at the level of individual antibodies. The objective of the research is to characterize the human neutralizing IgG response to EV71 in subjects who have survived endemic EV71 infection in Taiwan. Two innovative techniques will be used for studying the human antibody response to EV71. A proteomics approach will identify the specific EV71-reactive IgG clonotypes found in sera of naturally infected EV71 patients. This method is an innovative combination of protein mass spectrometry and a NextGen sequencing method that preserves natural HC:LC pairing. Concurrently, a novel hybridoma method of human antibody cloning will functionally screen human mAbs from the same patients in order to identify those with EV71 neutralizing activity. Correlation of these combined datasets will allow an assignment of functions to the exact antibodies present in the serum repertoire. This unprecedented level of detail about the human anti- EV71 antibody repertoire will enable studies to understand the function of antibodies in protection from EV71, including structural studies and animal modeling. The research will seek to identify pairs of non-cross-resistant mAbs with broad-spectrum neutralization activity that will establish proof-of-concept for an EV71 therapeutic intended for use in the USA.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2019 ( Subtotal = $0 )
2019	2017	LANKENAU INSTITUTE FOR MEDICAL RESEARCH	100 E LANCASTER AVE	WYNNEWOOD	PA	19096	MONTGOMERY	USA	Allergy and Infectious Diseases Research	000	2	8/27/2019	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2017 ( Subtotal = $200,209 )
2017	2017	LANKENAU INSTITUTE FOR MEDICAL RESEARCH	100 E LANCASTER AVE	WYNNEWOOD	PA	19096	MONTGOMERY	USA	Allergy and Infectious Diseases Research	000	2	3/23/2017	NON-COMPETING CONTINUATION	$200,209
														Subtotal = $200,209

Issue Date FY: 2016 ( Subtotal = $258,209 )
2016	2016	LANKENAU INSTITUTE FOR MEDICAL RESEARCH	100 LANCASTER AVENUE	WYNNEWOOD	PA	19096	MONTGOMERY	USA	Allergy and Infectious Diseases Research	000	1	4/12/2016	NEW	$258,209
														Subtotal = $258,209

Grand Total All Awards = $458,418

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Comprehensive functional assesment of the human antibody response to Enterovirus 71

Award Number: R21AI119368

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/13/2016

PERIOD OF PERFORMANCE END DATE: 03/31/2019

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer